Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis
Zhong-Guo Fan,1 Wen-Ling Zhang,2 Bing Xu,1 Jun Ji,1 Nai-Liang Tian,3 Sheng-Hu He1 1Department of Cardiology, Subei People’s Hospital of Jiangsu Province, Yangzhou University, Yangzhou, Jiangsu, China; 2Department of Geriatric Gastroenterology, First Affiliated Hospital, Nanjing Medical Un...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-02-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/comparisons-between-ticagrelor-and-clopidogrel-following-percutaneous--peer-reviewed-article-DDDT |
| _version_ | 1828392891811102720 |
|---|---|
| author | Fan ZG Zhang WL Xu B Ji J Tian NL He SH |
| author_facet | Fan ZG Zhang WL Xu B Ji J Tian NL He SH |
| author_sort | Fan ZG |
| collection | DOAJ |
| description | Zhong-Guo Fan,1 Wen-Ling Zhang,2 Bing Xu,1 Jun Ji,1 Nai-Liang Tian,3 Sheng-Hu He1 1Department of Cardiology, Subei People’s Hospital of Jiangsu Province, Yangzhou University, Yangzhou, Jiangsu, China; 2Department of Geriatric Gastroenterology, First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China; 3Department of Cardiology, Nanjing First Hospital, Nanjing Heart Center, Nanjing Medical University, Nanjing, Jiangsu, China Background: The efficacy and safety of ticagrelor following percutaneous coronary intervention for patients with acute coronary syndrome remains unclear. This study sought to evaluate clinical outcomes of ticagrelor as part of dual-antiplatelet treatment for these patients. Methods: PubMed, MEDLINE, Embase, and other Internet sources were searched for eligible citations. The primary end point was major adverse cardiovascular and cerebrovascular events, consisting of cardiovascular death, myocardial infarction, and stroke. The secondary end point was the occurrence of definite/probable stent thrombosis (ST). The risk of bleeding was chosen to be the safety end point. Results: Eleven clinical trials – six randomized trials and five observational trials – were finally analyzed. A tendency toward reduction in the risk of major adverse cardiovascular and cerebrovascular events was observed only with respect to ticagrelor (OR 0.83, 95% CI 0.66–1.03; P=0.091), which might have resulted from the lower risk of cardiovascular death (OR 0.78, 95% CI 0.68–0.89; P<0.001). The overall incidence of ST differed significantly between the ticagrelor group and the clopidogrel group (OR 0.74, 95% CI 0.59–0.93; P=0.009), but the risk of bleeding, regardless of major or minor bleeding, increased significantly. Conclusion: As part of dual-antiplatelet treatment following percutaneous coronary intervention, ticagrelor significantly reduced the risk of cardiovascular death and ST in acute coronary syndrome patients, but at the cost of bleeding. More powerful relevant randomized trials are still warranted to guide clinical decision-making. Keywords: ticagrelor, clopidogrel, dual antiplatelet treatment, percutaneous coronary intervention, acute coronary syndrome |
| first_indexed | 2024-12-10T07:29:19Z |
| format | Article |
| id | doaj.art-27ce9cef4d5a43ffa96af8ac74048d86 |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-12-10T07:29:19Z |
| publishDate | 2019-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-27ce9cef4d5a43ffa96af8ac74048d862022-12-22T01:57:37ZengDove Medical PressDrug Design, Development and Therapy1177-88812019-02-01Volume 1371973044212Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysisFan ZGZhang WLXu BJi JTian NLHe SHZhong-Guo Fan,1 Wen-Ling Zhang,2 Bing Xu,1 Jun Ji,1 Nai-Liang Tian,3 Sheng-Hu He1 1Department of Cardiology, Subei People’s Hospital of Jiangsu Province, Yangzhou University, Yangzhou, Jiangsu, China; 2Department of Geriatric Gastroenterology, First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China; 3Department of Cardiology, Nanjing First Hospital, Nanjing Heart Center, Nanjing Medical University, Nanjing, Jiangsu, China Background: The efficacy and safety of ticagrelor following percutaneous coronary intervention for patients with acute coronary syndrome remains unclear. This study sought to evaluate clinical outcomes of ticagrelor as part of dual-antiplatelet treatment for these patients. Methods: PubMed, MEDLINE, Embase, and other Internet sources were searched for eligible citations. The primary end point was major adverse cardiovascular and cerebrovascular events, consisting of cardiovascular death, myocardial infarction, and stroke. The secondary end point was the occurrence of definite/probable stent thrombosis (ST). The risk of bleeding was chosen to be the safety end point. Results: Eleven clinical trials – six randomized trials and five observational trials – were finally analyzed. A tendency toward reduction in the risk of major adverse cardiovascular and cerebrovascular events was observed only with respect to ticagrelor (OR 0.83, 95% CI 0.66–1.03; P=0.091), which might have resulted from the lower risk of cardiovascular death (OR 0.78, 95% CI 0.68–0.89; P<0.001). The overall incidence of ST differed significantly between the ticagrelor group and the clopidogrel group (OR 0.74, 95% CI 0.59–0.93; P=0.009), but the risk of bleeding, regardless of major or minor bleeding, increased significantly. Conclusion: As part of dual-antiplatelet treatment following percutaneous coronary intervention, ticagrelor significantly reduced the risk of cardiovascular death and ST in acute coronary syndrome patients, but at the cost of bleeding. More powerful relevant randomized trials are still warranted to guide clinical decision-making. Keywords: ticagrelor, clopidogrel, dual antiplatelet treatment, percutaneous coronary intervention, acute coronary syndromehttps://www.dovepress.com/comparisons-between-ticagrelor-and-clopidogrel-following-percutaneous--peer-reviewed-article-DDDTticagrelorclopidogreldual antiplatelet treatmentpercutaneous coronary interventionacute coronary syndromes |
| spellingShingle | Fan ZG Zhang WL Xu B Ji J Tian NL He SH Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis Drug Design, Development and Therapy ticagrelor clopidogrel dual antiplatelet treatment percutaneous coronary intervention acute coronary syndromes |
| title | Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis |
| title_full | Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis |
| title_fullStr | Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis |
| title_full_unstemmed | Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis |
| title_short | Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis |
| title_sort | comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome a comprehensive meta analysis |
| topic | ticagrelor clopidogrel dual antiplatelet treatment percutaneous coronary intervention acute coronary syndromes |
| url | https://www.dovepress.com/comparisons-between-ticagrelor-and-clopidogrel-following-percutaneous--peer-reviewed-article-DDDT |
| work_keys_str_mv | AT fanzg comparisonsbetweenticagrelorandclopidogrelfollowingpercutaneouscoronaryinterventioninpatientswithacutecoronarysyndromeacomprehensivemetaanalysis AT zhangwl comparisonsbetweenticagrelorandclopidogrelfollowingpercutaneouscoronaryinterventioninpatientswithacutecoronarysyndromeacomprehensivemetaanalysis AT xub comparisonsbetweenticagrelorandclopidogrelfollowingpercutaneouscoronaryinterventioninpatientswithacutecoronarysyndromeacomprehensivemetaanalysis AT jij comparisonsbetweenticagrelorandclopidogrelfollowingpercutaneouscoronaryinterventioninpatientswithacutecoronarysyndromeacomprehensivemetaanalysis AT tiannl comparisonsbetweenticagrelorandclopidogrelfollowingpercutaneouscoronaryinterventioninpatientswithacutecoronarysyndromeacomprehensivemetaanalysis AT hesh comparisonsbetweenticagrelorandclopidogrelfollowingpercutaneouscoronaryinterventioninpatientswithacutecoronarysyndromeacomprehensivemetaanalysis |